# Nuclide record alpha-therapy-roadmap (roadmap). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/roadmaps/alpha-therapy-roadmap/>
  a schema:CreativeWork ;
  nuclide:kind "roadmap" ;
  schema:identifier "alpha-therapy-roadmap" ;
  schema:name "Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline"@en ;
  schema:description "Alpha particles carry much more energy over a much shorter distance than the beta particles used in Lutathera and Pluvicto, so they can be more powerful against small clusters of cancer cells. The first alpha drug was approved in 2013; a wave of alpha versions of existing beta drugs is now in late-stage testing, and the isotopes are still scarce."@en ;
  schema:url <https://nuclide.cc/roadmaps/alpha-therapy-roadmap/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203971Orig1s000TOC.cfm>, <https://pubmed.ncbi.nlm.nih.gov/27390158/>, <https://clinicaltrials.gov/study/NCT05477576>, <https://www.sanofi.com/en/media-room/press-releases/2025/2025-10-08-05-00-00-3163053>, <https://www.terrapower.com/TerraPower-Isotopes-Breaks-Ground-on-Worlds-Largest-Actinium-225-Manufacturing-Facility-in-Philadelphia> ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/>, <https://nuclide.cc/isotopes/ra-223/>, <https://nuclide.cc/isotopes/pb-212/> ;
  nuclide:technologies <https://nuclide.cc/technologies/targeted-alpha-therapy/>, <https://nuclide.cc/technologies/actinium-225-supply/>, <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/prrt/> ;
  nuclide:drugs <https://nuclide.cc/drugs/radium-223/>, <https://nuclide.cc/drugs/ryz101/>, <https://nuclide.cc/drugs/fpi-2265/>, <https://nuclide.cc/drugs/ac225-psma/>, <https://nuclide.cc/drugs/alphamedix/> ;
  nuclide:companies <https://nuclide.cc/companies/rayzebio/>, <https://nuclide.cc/companies/fusion-pharma/>, <https://nuclide.cc/companies/novartis/>, <https://nuclide.cc/companies/orano-med/>, <https://nuclide.cc/companies/radiomedix/>, <https://nuclide.cc/companies/terrapower-isotopes/> ;
  nuclide:trials <https://nuclide.cc/trials/alsympca/>, <https://nuclide.cc/trials/action-1/>, <https://nuclide.cc/trials/alphabreak/>, <https://nuclide.cc/trials/alphamedix-02/> ;
  nuclide:people <https://nuclide.cc/people/clemens-kratochwil/>, <https://nuclide.cc/people/uwe-haberkorn/> ;
  nuclide:keyPapers <https://nuclide.cc/key-papers/paper-alsympca-radium-223-nejm-2013/> .